Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. The company's marketed product, Ocaliva? (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to, the company is developing OCA for multiple indications, including nonalcoholic steatohepatitis.
  • TickerICPT
  • ISINUS45845P1084
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

1 director bought

A director at Intercept Pharmaceuticals Inc bought 5,207 shares at 60.320USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in emerg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch